Susan Elaine Bates MD

Oncology•New York, NY

Division of Hematology/Oncology, Columbia University Medical Center. Senior Investigator, Medical Oncology Branch and Affiliates, National Cancer Institute

Request appointment

161 Fort Washington AvenueFloor 9New York, NY 10032
Book by Phone+1(765) 415-4613

Overview of Dr. Bates

Dr. Susan Bates is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital, NewYork-Presbyterian/Columbia University Irving Medical Center, and James J. Peters Veterans Affairs Medical Center. She received her medical degree from University of Arkansas For Medical Sciences College of Medicine and has been in practice 48 years. She is one of 403 doctors at New York-Presbyterian Hospital and one of 9 doctors at James J. Peters Veterans Affairs Medical Center who specialize in Oncology. She has more than 100 publications and over 500 citings.

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1982 - 1984
University of Arkansas for Medical Sciences (UAMS) College of MedicineResidency, Internal Medicine, 1978 - 1980
University of Arkansas For Medical Sciences College of MedicineClass of 1978

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

NJ State Medical License 2022 - 2027
AR State Medical License 1978 - 2026
NY State Medical License 2015 - 2026
MD State Medical License 1985 - 2018
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Editor in Chief The Oncologist, 2022
CMS Meaningful Use Stage 1 Certification Allscripts TouchWorks EHR (Complete), Allscripts, 2016-2017
CMS Meaningful Use Stage 1 Certification Allscripts TouchWorks EHR, Allscripts, 2016-2017

Clinical Trials

Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma Start of enrollment: 2001 Mar 08
Completed
Phase 2
Depsipeptide in Treating Patients With Solid Tumors Start of enrollment: 1997 Aug 01
Completed
Phase 1
Monoclonal Antibody Plus Chemotherapy in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2 Start of enrollment: 1999 Aug 01
Completed
Phase 2

Publications & Presentations

PubMed

Targeting of MEK and Autophagy in Pancreatic Adenocarcinoma and Analysis of Treatment Sensitivity in Preclinical and Clinical Models: MEKiAUTO.
Brian W Labadie, Aleksandar Obradovic, Alexander G Raufi, Urszula N Wasko, Lorenzo Tomassoni
JCO Precision Oncology. 2026-06-01
How to write an impactful review article?
Jianyou Gu, Susan E Bates, Zhe-Sheng Chen
Drug Discovery Today. 2026-05-01
Phase 2 study of azacitidine plus pembrolizumab as second-line treatment in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma.
Rachael A Safyan, Ruth A White, Tamas A Gonda, Shing M Lee, Jiying Han
The Oncologist. 2026-03-09

Journal Articles

Clinical Trials in Pancreatic Cancer: A Long Slog
Susan Bates, MD, The Oncologist

Authored Content

Epidermal Growth Factor Receptor (EGFR) Inhibitor PD153035 Reverses ABCG2-Mediated Multidrug Resistance in Non-Small Cell Lung Cancer: In Vitro and in VivoMarch 2018

Press Mentions

ORIGINAL ARTICLE Bioengineered miR-27b-3p and miR-328-3p Modulate Drug Metabolism and Disposition via the Regulation of Target ADME Gene ExpressionMay 16th, 2019
Susan Bates, M.D., and Antonio “Tito” Fojo, M.D., Ph.D.: Thirty Years of Research, Discovery, Service, and Mentorship at the National Cancer InstituteNovember 4th, 2015

Grant Support

Translational Studies Of The Histone Deacetylase Inhibitor RomidepsinNational Cancer Institute2010–2011
Investigation Of The ABC Half-Transporter ABCG2National Cancer Institute2010–2011
Clinical Studies To Circumvent Drug ResistanceNational Cancer Institute2010–2011
Translational Studies Of The Histone Deacetylase Inhibitor RomidepsinDivision Of Basic Sciences - Nci2009
Investigation Of The ABC Half-Transporter ABCG2Division Of Basic Sciences - Nci2009